Exploring the impact of variable power outputs on the efficacy and safety during microwave ablation for lung carcinoma: a real-world study

被引:0
|
作者
Cui, Song-Ping [1 ,2 ]
Zhao, Qing [1 ,2 ]
Wang, Jing [1 ,2 ,3 ]
Ji, Ying [1 ,2 ]
Miao, Jin-Bai [1 ,2 ]
Fu, Yi-Li [1 ,2 ]
Hu, Bin [1 ,2 ]
Chen, Shuo [1 ,2 ]
机构
[1] Capital Med Univ, Beijing Inst Resp Med, Dept Thorac Surg, 8 Gongtinan Rd, Beijing 100020, Peoples R China
[2] Capital Med Univ, Beijing Chao Yang Hosp, 8 Gongtinan Rd, Beijing 100020, Peoples R China
[3] Harvard Med Sch, Mass Gen Canc Ctr, Mass Gen Brigham, Boston, MA USA
关键词
Lung carcinoma; microwave ablation (MWA); power; complication; prognosis; CANCER; SURVIVAL; THERAPY;
D O I
10.21037/jtd-24-557
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Microwave ablation (MWA) is an important method for the treatment of lung cancer, but there is still a lack of standard guidelines for the selection of power. This study aimed to explore the effectiveness and safety of MWA at different power levels. Methods: The study gathered individuals underwent MWA for lung cancer between January 2012 and December 2020. All patients were divided into low power group and high power group based on the power of MWA. By intergroup comparisons, we clarified the differences between the two groups. Results: In this study, 265 participants were involved, with 192 in the low power group and 73 in the high power group. Compared to the low power group, the high power group had a significantly higher incidence of postoperative complications (63.0% vs. 24.0%). In the Kaplan-Meier analysis, overall survival (OS) and disease-free survival (DFS) of the high power group were both better than the low power group. We found through Cox regression analysis that smoking, tumor volume, tumor differentiation, gene mutation, neutrophil count, and lymphocyte count were independent factors affecting the OS of patients. Based on the above factors, we constructed a nomogram, with areas under the curve (AUCs) of 0.941, 0.903, and 0.905 for predicting 1-, 2-, and 3-year OS after MWA, respectively. Conclusions: While high-power MWA brings better long-term prognosis to patients, it also leads to an increase in postoperative complications. The application of a nomogram for stratifying the prognosis of patients may be a more feasible approach to further develop individualized treatment plans.
引用
收藏
页码:5031 / 5041
页数:12
相关论文
共 50 条
  • [1] Preoperative systemic immune-inflammation index-based nomogram for lung carcinoma following microwave ablation -a real world single center study
    Wang, Jing
    Cui, Song-ping
    Zhao, Qing
    Gao, Ya
    Ji, Ying
    Liu, Yi
    Miao, Jin-bai
    Fu, Yi-li
    Hu, Bin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [2] The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study
    Wang, Xishu
    Sun, Ximin
    Lei, Yongrong
    Fang, Lingyan
    Wang, Yuedi
    Feng, Kai
    Xia, Feng
    BMC CANCER, 2024, 24 (01)
  • [3] Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
    Zhang, Kun
    Ma, Xiya
    Gao, Hongjun
    Wang, Hong
    Qin, Haifeng
    Yang, Shaoxing
    Liu, Xiaoqing
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3409 - 3417
  • [4] Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population
    Peverelli, Giorgia
    Raimondi, Alessandra
    Ratta, Raffaele
    Verzoni, Elena
    Bregni, Marco
    Cortesi, Enrico
    Carteni, Giacomo
    Fornarini, Giuseppe
    Facchini, Gaetano
    Buti, Sebastiano
    Galli, Luca
    Tucci, Marcello
    Prisciandaro, Michele
    Procopio, Giuseppe
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 291 - 298
  • [5] Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population
    Liu, Yuanyuan
    Yang, Xinyi
    Wang, Yan
    Xie, Songzuo
    Li, Minxing
    You, Jinqi
    Tang, Yan
    Zhao, Jingjing
    Weng, Desheng
    BMC CANCER, 2024, 24 (01)
  • [6] Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
    Yuan, Jing
    Cheng, Feng
    Xiao, Guodong
    Wang, Xiaofeng
    Fan, Huijie
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
    Wang, Dong-Xu
    Yang, Xu
    Lin, Jian-Zhen
    Bai, Yi
    Long, Jun-Yu
    Yang, Xiao-Bo
    Seery, Samuel
    Zhao, Hai-Tao
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (30) : 4465 - 4478
  • [8] Efficacy and safety of reduced-dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real-world observational study
    Ouyang, Ganlu
    Liu, Yanyang
    Liu, Jiewei
    Huang, Lin
    Luo, Feng
    Li, Lu
    CANCER MEDICINE, 2023, 12 (18): : 18679 - 18690
  • [9] Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study
    Xiangwei Xu
    Ruya Li
    Peizhen Zhu
    Penghai Zhang
    Jun Chen
    Yongsheng Lin
    Yinqiao Chen
    World Journal of Surgical Oncology, 19
  • [10] Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study
    Xu, Xiangwei
    Li, Ruya
    Zhu, Peizhen
    Zhang, Penghai
    Chen, Jun
    Lin, Yongsheng
    Chen, Yinqiao
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)